研究等業績 - その他 - 髙橋　直人

The Combination of Interferon-Alpha and Ponatinib Enables Faster and Deeper Molecular Responses in Patient with De Novo Blast Crisis of CML: Interferon-Alpha May Return as a CML Treatment.

Kunio Hayashi, Kazuhiro Ikegame, Naoto Takahashi

Case reports in hematology   2021   5518727 - 5518727   2021年

In the era of tyrosine kinase inhibitor (TKI) treatment, its effectiveness in treating chronic myelogenous leukemia (CML) has been improved, ensuring the same prognosis as that of healthy people of the same age. However, there are some patients with de novo blast crisis that undergoes acute conversion from the time of diagnosis and does not respond to TKI treatment, especially in the older patients. Here, we present a case of an older patient with de novo lymphoid crisis who was first treated with a combination of TKI and chemotherapy, but it was difficult to maintain a durable deep molecular response (DMR). After he achieved major molecular response (MMR) or less, it was possible to suppress IS% to DMR by performing a combined treatment with interferon-α (IFN-α) and ponatinib. It is considered that DMR can be maintained by the combination of the two-way action of IFN-α, that is, the transfer of dormant CML stem cells to the cellcycle and the activation of a specific immune response to CML cells. This clinical result suggests the possibility of the re-emergence of IFN-α, which has been used a therapeutic drug in the past.

DOI PubMed

Successful salvage therapy of D-PACE combined with pomalidomide in a patient with triple-class refractory secondary plasma cell leukemia(和訳中)

Kobayashi Takahiro, Kuroki Jun, Kobayashi Isuzu, Saito Masaya, Fujishima Masumi, Ubukawa Kumi, Fujishima Naohito, Kameoka Yoshihiro, Nanjo Hiroshi, Takahashi Naoto

International Journal of Myeloma ( (一社)日本骨髄腫学会 )  11 ( 4 ) 27 - 31   2021年

Successful salvage therapy of D-PACE combined with pomalidomide in a patient with triple-class refractory secondary plasma cell leukemia

KOBAYASHI Takahiro, KUROKI Jun, KOBAYASHI Isuzu, SAITO Masaya, FUJISHIMA Masumi, UBUKAWA Kumi, FUJISHIMA Naohito, KAMEOKA Yoshihiro, NANJO Hiroshi, TAKAHASHI Naoto

International Journal of Myeloma ( 一般社団法人 日本骨髄腫学会 )  11 ( 4 ) 27 - 31   2021年

<p>Novel agents have dramatically improved the prognosis of multiple myeloma (MM). However, the prognosis of MM resistant to several classes of novel agents and secondary plasma cell leukemia (sPCL) is poor. In such cases, cisplatin, doxorubicin, cyclophosphamide, and etoposide (PACE)-based regimens are considered in combination with dexamethasone, thalidomide, and bortezomib. Herein, we report the case of a 47-year-old patient with Bence Jones Protein (BJP)-λ-type MM, primary refractory to bortezomib, lenalidomide, and dexamethasone (VRd) therapy, which subsequently progressed to sPCL accompanied with the acquired 17p deletion. Although the patient was also refractory to daratumumab-based therapy (triple-class refractory MM), he was successfully treated with dexamethasone and pomalidomide with PACE (DP-PACE) therapy, and after three cycles, he achieved complete remission (CR) and bridged to allogeneic stem cell transplantation (SCT). To the best of our knowledge, this is the first report of DP-PACE regimen, which may be considered for patients with relapsed refractory MM as a bridge to SCT.</p>

DOI CiNii Research

有毛細胞白血病を疑うリンパ球増多症で発症し,細胞表面解析から診断に至った慢性NK細胞増多症の一例

齊藤由紀子, 小林敬宏, 小林敬宏, 鎌田幸子, 亀岡吉弘, 菊地優子, 永沼綾子, 富谷陽子, 高橋直人, 嵯峨知生, 嵯峨知生, 植木重治, 植木重治

日本検査血液学会雑誌   22   2021年

J-GLOBAL

腎生検が治療の契機となった慢性リンパ球性白血病

今泉 ちひろ, 齋藤 綾乃, 北舘 明宏, 加賀 一, 齋藤 雅也, 奈良 瑞穂, 高橋 直人

日本腎臓学会誌 ( (一社)日本腎臓学会 )  62 ( 6 ) 580 - 580   2020年09月

Pharmacokinetics of dasatinib in a hemodialysis patient with chronic myeloid leukemia and chronic kidney disease

Mori J.

International Journal of Hematology ( International Journal of Hematology )  112 ( 1 ) 115 - 117   2020年07月

国内共著

DOI

Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia

Hino M.

International Journal of Hematology ( International Journal of Hematology )  112 ( 1 ) 24 - 32   2020年07月  [査読有り]

国内共著

DOI

Hypereosinophilic syndrome with abundant Charcot-Leyden crystals in spleen and lymph nodes.

Masahide Takeda, Shigeharu Ueki, Yohei Yamamoto, Miho Nara, Mineyo Fukuchi, Katsutoshi Nakayama, Yasufumi Omori, Naoto Takahashi, Makoto Hirokawa

Asia Pacific allergy   10 ( 3 ) e24   2020年07月

Hypereosinophilic syndrome, which is characterized by eosinophilia in the peripheral blood, often causes various organ disorders. Charcot-Leyden crystals are recognized features of various diseases, such as parasite infection and asthma, and are known to be classic hallmarks of eosinophilic inflammation. Our recent study revealed the mechanism of Charcot-Leyden crystal formation (i.e., galectin-10 crystallization), namely the involvement of eosinophil extracellular trap cell death, a nonapoptotic cell death. Here we report an autopsy case of a 57-year-old man who had died of hypereosinophilic syndrome. We found numerous eosinophil extracellular trap cell death-associated Charcot-Leyden crystals in the spleen and lymph nodes. Observation of abdominal lymph nodes by electron microscopy revealed eosinophil extracellular traps and free extracellular granules, which are characteristic of typical eosinophil extracellular trap cell death. In this case, we observed various sizes of Charcot-Leyden crystals that were stained with anti-galectin-10 immunofluorescent staining. Further studies are required to understand the pathophysiological roles of Charcot-Leyden crystals and these may lead to the development of novel therapeutic modalities for severe eosinophilic inflammation.

DOI PubMed

ループス腎炎V型におけるexostosin1(EXT1)/exostosin2(EXT2)の検討

今泉 ちひろ, 阿部 史人, 齋藤 綾乃, 齋藤 雅也, 奈良 瑞穂, 小澤 政豊, 小松田 敦, 高橋 直人

日本腎臓学会誌 ( (一社)日本腎臓学会 )  62 ( 4 ) 268 - 268   2020年07月

ループス腎炎V型におけるextosin1(EXT1)/extosin2(EXT2)の検討

今泉 ちひろ, 阿部 史人, 齋藤 綾乃, 齋藤 雅也, 奈良 瑞穂, 小澤 政豊, 小松田 敦, 高橋 直人

日本腎臓学会誌 ( (一社)日本腎臓学会 )  62 ( 4 ) 268 - 268   2020年07月

An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia

Ko T.K.

Blood ( Blood )  135 ( 26 ) 2337 - 2353   2020年06月  [査読有り]

国際共著

DOI

PCd療法により維持透析を離脱し完全寛解を達成したpenta-refractory IgD-λ型多発性骨髄腫

池田 翔, 山田 雅浩, 黒木 航, 齋藤 綾乃, 藤岡 優樹, 鵜生川 久美, 亀岡 吉弘, 高橋 直人

臨床血液 ( (一社)日本血液学会-東京事務局 )  61 ( 4 ) 420 - 420   2020年04月

R-CHOP療法に奏効しているGCB typeのdouble expressor lymphoma(DEL)

山田 雅浩, 亀岡 吉弘, 鵜生川 久美, 齋藤 綾乃, 藤岡 優樹, 池田 翔, 高橋 直人

臨床血液 ( (一社)日本血液学会-東京事務局 )  61 ( 4 ) 419 - 419   2020年04月

CD7-Positive Diffuse Large B-Cell Lymphoma Presenting as an Intranasal Tumor.

Kazuaki Teshima, Masaaki Kume, Yasushi Kawaharada, Takashi Saito, Ko Abe, Sho Ikeda, Hideaki Ohyagi, Megumi Zuguchi, Masashi Zuguchi, Yosuke Kubota, Yoshitaka Enomoto, Masahito Miura, Satsuki Takahashi, Masahiro Saito, Ken Saito, Naoto Takahashi

Case reports in hematology   2020   1514729 - 1514729   2020年

We report a case of a 74-year-old man with a cluster of differentiation (CD) 7-positive diffuse large B-cell lymphoma (DLBCL) in the right nasal cavity. Flow cytometry analyses showed CD7 and CD20 positivity in tumor cells. The patient received 6 cycles of R-CHOP plus local radiation therapy because positron emission tomography-computed tomography after R-CHOP revealed an intranasal lesion. The patient achieved complete remission (CR) after radiation therapy. The frequency of CD7-positive DLBCL is rare, and only 11 cases with follow-up of clinical course have been reported thus far. CR or partial response was noted in 8 of 11 cases after receiving rituximab combined with chemotherapy. In total, 9 of 12 cases involved the development of extranodal lesions, which occurred as an intranasal tumor in 3 cases. It is important to examine the clinical features by accumulation of further cases.

DOI PubMed

多発性骨髄腫においてCD38低発現はt(11;14)転座及びBCL2依存性に関連する

北舘明宏, 北舘明宏, 池田翔, 成田健太郎, 三浦大典, 寺尾俊紀, 津島隆史, 竹内正美, 高橋直人, 末永孝生

日本血液学会学術集会抄録(Web)   82nd   2020年

J-GLOBAL

コントロール不良な高齢発症関節リウマチに後天性血友病を合併した一例

今泉 ちひろ, 阿部 史人, 齋藤 綾乃, 齋藤 雅也, 藤岡 優樹, 奈良 瑞穂, 郭 永梅, 奈良 美保, 小澤 政豊, 吉岡 智子, 小松田 敦, 高橋 直人

日本リウマチ学会北海道・東北支部学術集会抄録集 ( (一社)日本リウマチ学会-北海道・東北支部 )  29回   86 - 86   2019年11月

B-ALL移植後再発症例におけるblinatumomabの治療反応性と免疫プロファイル

小林 敬宏, 鵜生川 久美, 藤島 眞澄, 亀岡 吉弘, 藤島 直仁, 高橋 直人

臨床血液 ( (一社)日本血液学会-東京事務局 )  60 ( 11 ) 1596 - 1597   2019年11月

器質化肺炎と肥厚性硬膜炎にて発症した難治性IgG4関連疾患

阿部 史人, 斎藤 綾乃, 斎藤 雅也, 奈良 瑞穂, 郭 永梅, 奈良 美保, 吉岡 智子, 小松田 敦, 高橋 直人

日本リウマチ学会北海道・東北支部学術集会抄録集 ( (一社)日本リウマチ学会-北海道・東北支部 )  29回   89 - 89   2019年11月

Effect of low platelet HLA-C expression on donor-specific antibody depletion following platelet transfusion from a corresponding HLA donor

Yamashita T.

Bone Marrow Transplantation ( Bone Marrow Transplantation )  54 ( 10 ) 1713 - 1716   2019年10月

DOI PubMed

ヘキソキナーゼ-2は低酸素誘導性オートファジーを促進し、多発性骨髄腫のプロテアソーム阻害薬抵抗性を誘導する(Hexokinase-2(HK2) promotes hypoxia-inducible autophagy, leading to proteasome inhibitor resistance in multiple myeloma)

池田 翔, 阿部 史人, 北舘 明宏, 高橋 直人, 田川 博之

日本癌学会総会記事 ( 日本癌学会 )  78回   J - 1016   2019年09月